Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma

Cell Death and Differentiation

Volumn 23, Issue 4, 2016, Pages 640-653

  Renner, G ^a   Janouskova, H ^a   Noulet, F ^a   Koenig, V ^a   Guerin, E ^a   Bar S ^a,b   Nuesch, J ^b   Rechenmacher, F ^c   Neubauer, S ^c   Kessler, H ^c   Blandin, A F ^a   Choulier, L ^a   Etienne Selloum, N ^a   Lehmann, M ^a   Lelong Rebel, I ^a   Martin, S ^a   Dontenwill, M ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; CASPASE 3; CASPASE 8; INTEGRIN ALPHA 5 BETA 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PHOSPHOPROTEIN; PHOSPHOPROTEIN ENRICHED IN ASTROCYTES 15; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PEA15 PROTEIN, HUMAN; SIGNAL PEPTIDE; TP53 PROTEIN, HUMAN; VERY LATE ACTIVATION ANTIGEN 5;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ASTROCYTE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; ASTROCYTES; CELL LINE, TUMOR; GLIOMA; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTEGRIN ALPHA5BETA1; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84960970225     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.131     Document Type: Article

References (69)

1. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
2. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012; 33: 405-412.
3. Eke I, Cordes N. Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol 2014; 31: 65-75.
4. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008; 8: 604-617.
5. Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL. Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 2010; 9: 152.
6. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011; 30: 1566-1576.
7. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha 5 beta 1 and fibronectin. Cancer Res 2010; 70: 5238-5248.
8. Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E et al. Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res 2012; 72: 3463-3470.
9. Holmes KM, Annala M, Chua CYX, Dunlap SM, Liu YX, Hugen N et al. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappa B network. Proc Natl Acad Sci USA 2012; 109: 3475-3480.
10. Schaffner F, Ray AM, Dontenwill M. Integrin alpha5beta1, the fibronectin receptor, as a pertinent therapeutic target in solid tumors. Cancers 2013; 5: 27-47.
11. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
13. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. Embo Rep 2014; 15: 1243-1253.
14. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100-1108.
15. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
16. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127-U1247.
17. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR et al. The somatic genomic landscape of glioblastoma. Cell 2013; 155: 462-477.
18. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
19. Viotti J, Duplan E, Caillava C, Condat J, Goiran T, Giordano C et al. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Oncogene 2014; 33: 1764-1775.
20. Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13: 217-236.
21. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006; 13: 921-926.
22. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665.
23. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
24. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K et al. Alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 2010; 127: 1240-1248.
25. Villalonga-Planells R, Coll-Mulet L, Martinez-Soler F, Castano E, Acebes JJ, Gimenez-Bonafe P et al. Activation of p53 by Nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLos One 2011; 6: e18588.
26. Janouskova H, Ray AM, Noulet F, Lelong-Rebel I, Choulier L, Schaffner F et al. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target alpha5 integrin in colon cancer cells. Cancer Lett 2013; 336: 307-318.
27. Ray AM, Schaffner F, Janouskova H, Noulet F, Rognan D, Lelong-Rebel I et al. Single cell tracking assay reveals an opposite effect of selective small non-peptidic alpha5beta1 or alphavbeta3/beta5 integrin antagonists in U87MG glioma cells. Biochimica et Biophysica acta 2014; 1840: 2978-2987.
28. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006; 13: 1776-1788.
29. Trencia A, Perfetti A, Cassese A, Vigliotta G, Miele C, Oriente F et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol Cell Biol 2003; 23: 4511-4521.
30. Stassi G, Garofalo M, Zerilli M, Ricci-Vitiani L, Zanca C, Todaro M et al. PED mediates AKTdependent chemoresistance in human breast cancer cells. Cancer Res 2005; 65: 6668-6675.
31. Marconi A, Atzei P, Panza C, Fila C, Tiberio R, Truzzi F et al. FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J Cell Sci 2004; 117: 5815-5823.
32. Condorelli G, Vigliotta G, Cafieri A, Trencia A, Andalo P, Oriente F et al. PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis. Oncogene 1999; 18: 4409-4415.
33. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 2014; 21: 612-623.
34. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao WJ, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441-453.
35. McKenzie JA, Liu T, Goodson AG, Grossman D. Survivin enhances motility of melanoma cells by supporting Akt activation and alpha 5 integrin upregulation. Cancer Res 2010; 70: 7927-7937.
36. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL et al. Survivin promotion of melanoma metastasis requires upregulation of alpha(5) integrin. Carcinogenesis 2013; 34: 2137-2144.
37. DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012; 18: 2930-2942.
38. Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A et al. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem 2003; 278: 52587-52597.
39. Schiller HB, Hermann MR, Polleux J, Vignaud T, Zanivan S, Friedel CC et al. Beta(1)-and alpha(v)-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectinbased microenvironments. Nat Cell Biol 2013; 15: 625-636.
40. Sulzmaier F, Opoku-Ansah J, Ramos JW. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter. Small GTPases 2012; 3: 173-177.
41. Petalidis LP, Oulas A, Backlund M, Wayland MT, Liu L, Plant K et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 2008; 7: 1013-1024.
42. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C et al. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neuro-Oncol 2010; 100: 449-457.
43. Eckert A, Bock BC, Tagscherer KE, Haas TL, Grund K, Sykora J et al. The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/ MAP kinase pathway. Oncogene 2008; 27: 1155-1166.
44. Hao CH, Beguinot F, Condorelli C, Trencia A, Van Meir EG, Yong VW et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001; 61: 1162-1170.
45. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 2005; 65: 11469-11477.
46. Funke V, Lehmann-Koch J, Bickeboller M, Benner A, Tagscherer KE, Grund K et al. The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas. Cancer Lett 2013; 335: 431-440.
47. Condorelli G, Trencia A, Vigliotta G, Perfetti A, Goglia U, Cassese A et al. Multiple members of the mitogen-activated protein kinase family are necessary for PED/PEA-15 anti-apoptotic function. J Biol Chem 2002; 277: 11013-11018.
48. Hendruschk S, Wiedemuth R, Aigner A, Topfer K, Cartellieri M, Martin D et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011; 13: 1074-1089.
49. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K et al. Expression of survivin in astrocytic tumors-Correlation with malignant grade and prognosis. Cancer 2003; 97: 1077-1083.
50. Guvenc H, Pavlyukov MS, Joshi K, Kurt H, Banasavadi-Siddegowda YK, Mao P et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin Cancer Res 2013; 19: 631-642.
51. Lanvin O, Monferran S, Delmas C, Couderc B, Toulas C, Cohen-Jonathan-Moyal E. Radiation-induced mitotic cell death and glioblastoma radioresistance: a new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1 alpha and survivin in U87 cells. Eur J Cancer 2013; 49: 2884-2891.
52. Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis 2014; 5: e1543.
53. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011; 16: 485-494.
54. Cheng SM, Chang YC, Liu CY, Lee JY, Chan HH, Kuo CW et al. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol 2015; 172: 214-234.
55. Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci 2014; 15: 2494-2516.
56. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M et al. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/ survivin pathway. J Biol Chem 2003; 278: 50402-50411.
57. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
58. Li H, Zhang Y, Strose A, Tedesco D, Gurova K, Selivanova G. Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis. Cell Death Differ 2014; 21: 1493-1502.
59. Issaeva N, Bozko P, Enge M, Protopopova M, LGGC Verhoef, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328.
60. de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG. Chk2 mediates RITA-induced apoptosis. Cell Death Differ 2012; 19: 980-989.
61. Chen YC, Chan JY, Chiu YL, Liu ST, Lozano G, Wang SL et al. Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death Differ 2013; 20: 732-743.
62. Zhang HH, Li SZ, Zhang ZY, Hu XM, Hou PN, Gao L et al. Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage. Cell Death Differ 2014; 21: 1656-1663.
63. Liu J, Zhang C, Wang XL, Ly P, Belyi V, Xu-Monette ZY et al. E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis. Cell Death Differ 2014; 21: 1792-1804.
64. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, Garza D et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012; 21: 793-806.
65. KracikovaM, Akiri G, George A, Sachidanandam R, Aaronson SA. A thresholdmechanismmediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013; 20: 576-588.
66. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-2728.
67. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
68. Neubauer S, Rechenmacher F, Beer AJ, Curnis F, Pohle K, D'Alessandria C et al. Selective imaging of the angiogenic relevant integrins alpha5beta1 and alphavbeta3. Angewandte Chemie 2013; 52: 11656-11659.
69. Lehmann M, Rabenandrasana C, Tamura R, Lissitzky JC, Quaranta V, Pichon J et al. A monoclonal antibody inhibits adhesion to fibronectin and vitronectin of a colon carcinoma cell line and recognizes the integrins alpha v beta 3, alpha v beta 5, and alpha v beta 6. Cancer Res 1994; 54: 2102-2107.